Table 4 Incidence rates of URTI in the total study population.

From: A randomised controlled study shows supplementation of overweight and obese adults with lactobacilli and bifidobacteria reduces bodyweight and improves well-being

 

Incidence Rate (per 100 person days)

p value

Active

Placebo

URTI Symptoms

1.30

2.16

 

   IRR (95% CI)

0.60 (0.52, 0.70)

<0.0001

Individual URTI symptoms

 Sneezing

0.71

1.31

 

   IRR (95% CI)

0.54 (0.44, 0.66)

<0.0001

 Cough

0.38

0.57

 

   IRR (95% CI)

0.67 (0.50, 0.90)

0.0073

 Runny nose

0.46

0.52

 

   IRR (95% CI)

0.89 (0.67, 1.18)

0.4268

 Blocked nose

0.46

0.64

 

   IRR (95% CI)

0.72 (0.55, 0.95)

0.0181

 Sore Throat

0.25

0.31

 

   IRR (95% CI)

0.80 (0.55, 1.17)

0.2512

Other symptoms

 Headache

1.08

1.58

 

   IRR (95% CI)

0.68 (0.58, 0.81)

<0.0001

 Earache

0.08

0.17

 

   IRR (95% CI)

0.48 (0.27, 0.88)

0.0173

 Muscle pain

0.28

0.42

 

   IRR (95% CI)

0.67 (0.48, 0.95)

0.0225

 Chest wheeze

0.09

0.15

 

   IRR (95% CI)

0.62 (0.34, 1.12)

0.1112

 Itchy eyes

0.19

0.23

 

   IRR (95% CI)

0.80 (0.52, 1.24)

0.3218

Antibiotic usage

0.08

0.08

 

   IRR (95% CI)

0.94 (0.46, 1.89)

0.8552

  1. Data is presented as incidence rate or incidence rate ratios (IRR) of 110 participants per group with 95% CIs and p values were calculated using a GLM with Poisson distribution and log link function. CI, confidence interval.
Back to article page